Skin capillary density in ovarian cancer; a potential biomarker of Bevacizumab treatment

被引：0
|
作者：
Cass, G. [1 ]
Newton, C. [2 ]
Pawade, J. [3 ]
Kanavou, S. [1 ]
机构：
[1] Univ Bristol, Bristol, Avon, England
[2] Univ Hosp, Bristol, Avon, England
[3] North Bristol Trust, Bristol, Avon, England
来源：
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 2021年 / 128卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
2359
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [21] Ovarian cancer methylome and its potential as biomarker
    Brait, Mariana
    Maldonado, Leonel
    Begum, Shahnaz
    Loyo, Myriam
    Poeta, Maria Luana
    Fazio, Vito
    Ongenaert, Mate
    Van Criekinge, Wim
    Sidransky, David
    Hoque, Mohammad
    [J]. CANCER RESEARCH, 2009, 69
  • [22] Osteopontin as a potential diagnostic biomarker for ovarian cancer
    Kim, JH
    Skates, SJ
    Uede, T
    Wong, KK
    Schorge, JO
    Feltmate, CM
    Berkowitz, RS
    Cramer, DW
    Mok, SC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1671 - 1679
  • [23] Bevacizumab treatment and quality of life in advanced ovarian cancer
    Canevari, Silvana
    Raspagliesi, Francesco
    Lorusso, Domenica
    [J]. FUTURE ONCOLOGY, 2013, 9 (07) : 951 - 954
  • [24] Bevacizumab and other biologics for the treatment of epithelial ovarian cancer
    Markman, Maurie
    [J]. 13TH WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY (COGI) HELD JOINTLY WITH THE GERMAN SOCIETY OF OBSTETRICS & GYNECOLOGY, 2010, : 41 - 44
  • [25] An economic analysis of bevacizumab in recurrent treatment of ovarian cancer
    Chan, J.
    Monk, B.
    Fuh, K.
    Urban, R.
    Hu, L.
    Caughey, A.
    Yu, X.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S29 - S30
  • [26] Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment
    Ding, Shan-Shan
    Li, Li
    Yu, Chun-Xia
    [J]. JOURNAL OF BUON, 2014, 19 (04): : 965 - 972
  • [27] Is there a role for repeated treatment with bevacizumab in patients with ovarian cancer?
    Richardson, D. L.
    Seamon, L. G.
    Hurt, J. D.
    Backes, F. J.
    Copeland, L. J.
    Fowler, J. M.
    Cohn, D. E.
    O'Malley, D. M.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S60 - S60
  • [28] 89Zr-bevacizumab PET as an early biomarker for response to everolimus treatment in an ovarian cancer xenograft model
    van Scheltinga, Anton G. T. Terwisscha
    van der Bilt, Arne R. M.
    Timmer-Bosscha, Hetty
    Schroder, Carolien P.
    Pot, Linda
    Kosterink, Jos G. W.
    van der Zee, Ate G. J.
    Lub-de Hooge, Marjolijn N.
    de Jong, Steven
    de Vries, Elisabeth G. E.
    Reyners, An K. L.
    [J]. CANCER RESEARCH, 2012, 72
  • [29] Bevacizumab and ovarian cancer
    Sato, Shinya
    Itamochi, Hiroaki
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2012, 24 (01) : 8 - 13
  • [30] Bevacizumab in ovarian cancer
    [J]. Nature Reviews Cancer, 2012, 12 (2) : 83 - 83
12345